Antiphospholipid Syndrome in Pregnancy – One of Hematology’s Most Complex Challenges – RPTH
RPTH Journal shared a post on LinkedIn about a recent article by Andrew J. Doyle, adding:
“Antiphospholipid syndrome in pregnancy: one of hematology’s most complex challenges
Antiphospholipid syndrome (APS) is a multisystem autoimmune disorder that significantly raises the risk of blood clots and adverse pregnancy outcomes.
Diagnosing it is often difficult, treatment options remain limited – and pregnancy adds a whole new layer of complexity.
A state-of-the-art review in RPTH Journal based on a lecture presented at the International Society on Thrombosis and Haemostasis (ISTH) 2025 Congress, offers a hematologic perspective on APS management during pregnancy, including prepregnancy counseling and thrombosis-related issues.
Key takeaways:
- APS carries high risks of thrombosis and late adverse pregnancy outcomes
- Management relies on anticoagulation and close specialist monitoring
- Risk stratification remains a major unmet need
Few novel treatments are on the horizon…
This review focuses primarily on late pregnancy complications and thrombotic issues rather than earlier events such as recurrent miscarriage, which fall more within the obstetric perspective.
More than 40 years after the initial description of APS by Graham Hughes, there is still much to improve, especially in personalizing treatment to enhance outcomes for pregnant patients.”
Oliver Tiebel, Medical Director, Laboratory Director MVZ at the Carl Gustav Carus University Hospital Dresden GmbH, reposted RPTH’s a post on LinkedIn:
“Very interesting paper … great compilation covering this extreme important issue … many thx to the authors Andrew Doyle, Catrin Cox and Karen Breen”
Title: Antiphospholipid syndrome and pregnancy – a hematologic perspective
Authors: Andrew J. Doyle, Catrin Cox, Karen A. Breen
Read the Full Article on RPTH
Stay updated on all scientific advances with Hemostasis Today.
-
Jul 5, 2026, 21:06Heghine Khachatryan: Toward Personalized Management of Glanzmann Thrombasthenia
-
Jul 5, 2026, 21:06Priyanka Kumari: IV Fluids and Isotonic Solution
-
Jul 5, 2026, 21:05Ahmed Rizq: Would You Thrombolyse a Stable Patient?
-
Jul 5, 2026, 21:03Emmanuel Obeng Ofori: Diagnosing Anaemia – Why Treating the Root Cause Matters More Than Simply Raising the Haemoglobin
-
Jul 5, 2026, 21:02Mohit Koladia: The Pharmacist’s Role in Stroke Prevention for Atrial Fibrillation
-
Jul 5, 2026, 20:22J. Meireles-Brandao: Exploring the Approach to Thrombophillias
-
Jul 5, 2026, 20:13Kavya Keerthana: The Platelet Count Everyone Calls ‘Reactive’ Until It Isn’t
-
Jul 5, 2026, 20:00Paul Kariuki: Why Altruism Isn’t Enough to Save Kenya’s Blood System
-
Jul 5, 2026, 19:53Tareq Abadl: Post-Transfusion Reactions – Can You Identify the Cause?